You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Patients with m2 antibodies: what diagnosis and follow-up are they given?
  1. E A L Byrne1,
  2. R Katbamna1,
  3. C Scott1,
  4. C Blanshard2,
  5. R Marley1,
  6. S W Coppack1,
  7. G R Foster1
  1. 1The Royal London Hospital, Whitechapel, London, UK
  2. 2Hommerton Hospital, London, UK
  1. Correspondence to Dr E A L Byrne, ICMS The Royal London Hospital, Whitechapel Road, London,E1 1BB, UK; elizabethbyrne{at}doctors.org.uk

https://doi.org/10.1136/gut.2009.190769

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In a recent issue of Gut Feuchinger et al report a novel marker antibody for primary biliary cirrhosis (PBC) which may become useful in the diagnosis of PBC in the future.1 At present diagnosis is based on the presence of the M2 substrate of anti-mitochondrial antibody (AMA) in the sera and liver function tests. The American Association for the Study of Liver Disease (AASLD) recommend that a diagnosis of PBC can be made with a positive M2 antibody and cholestatic liver biochemistry (biopsy can be used to confirm) and that patients who are M2 positive only should be followed up with annual …

    View Full Text

    Linked Articles

    • PostScript
      Author's response
      Reinhild Klein
      Gut 2010; 59 859-860 Published Online First: 13 May 2010. doi: 10.1136/gut.2009.199554